Introduction: Diabetes mellitus (DM) is a major cause of chronic kidney disease (CKD) worldwide. The sodium-glucose co-transporter-2 inhibitors (iSGLT2) showed excellent results in reducing proteinuria and kidney disease progression, reason that led to their inclusion as first-line treatment in international guidelines in patients with DM and CKD. Objective: Show the clinical interest of iSGLT2 in reducing proteinuria. Clinical Case: We report a case of a 68-year-old male patient, with a pathological history of arterial hypertension, DM with known target organ damage (retinopathy and nephropathy), dyslipidemia, heart failure with reduced left ventricular ejection fraction and diabetic kidney disease at a G2A3 stage. The patient had been followed up in our Nephrology department since 2019 and for the last year, he had a total proteinuria of about 5g/day, already under the maximum dose tolerated of the renin-angiotensin-aldosterone system inhibitor. For this reason, during de 2021 nephrology appointment, it was decided to introduce empagliflozin at a dose of 10 mg per day. The patient was re-evaluated about three months later, showing an almost 70% reduction in proteinuria, with 1.5g of protein in 24-hour urine. Discussion and Conclusion: Although this is a report of only one case, it is in line with what has been demonstrated in different clinical studies and shows the interest that this oral antidiabetics class has in the control of proteinuria, one of the most important factors in the progression of kidney disease.